DangER: protein ovERload. Targeting protein degradation to treat myeloma
about
Panobinostat for the treatment of multiple myeloma: the evidence to dateHaloTag technology: a versatile platform for biomedical applicationsAutophagy in plasma cell pathophysiologyTransmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle traffickingNovel therapeutic strategies for multiple myelomaUpdate on the optimal use of bortezomib in the treatment of multiple myelomaMultiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsStimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum StressA plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cellsInadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97Global cellular response to chemotherapy-induced apoptosis.Proteomic analyses of brain tumor cell lines amidst the unfolded protein responseThe endoplasmic reticulum in plant immunity and cell death.Bortezomib for the treatment of previously untreated multiple myeloma.Heat shock proteins in multiple myelomaCarfilzomib in multiple myeloma.Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis.Targeting CK2-driven non-oncogene addiction in B-cell tumors.The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathwayHsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stressCaspases and their substrates.Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.α-Asarone blocks 7β-hydroxycholesterol-exposed macrophage injury through blocking elF2α phosphorylation and prompting beclin-1-dependent autophagyUnderstanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application.Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma.GRP78 Promotes Neural Stem Cell Antiapoptosis and Survival in Response to Oxygen-Glucose Deprivation (OGD)/Reoxygenation through PI3K/Akt, ERK1/2, and NF-κB/p65 Pathways.Multiple myeloma
P2860
Q26778674-579C3CB4-E2D9-44C9-BE4F-15BA23001FC3Q26997400-DC891AED-516B-4CDD-994F-A6F5625BF2BCQ27015920-9A165C43-BD5B-42A7-804F-5BE5E391E501Q27331909-617B529F-99EC-4254-BA02-343C8C5112B6Q28081590-87CBBBE8-445A-4A8A-AF6D-4848B2457866Q33440007-708F2047-3CE1-40F4-8834-643B145E0EBFQ34038854-CFB2A0BB-1606-4201-8E44-B427F20E1E0DQ34508337-7DF63ED3-766F-4F7F-971E-9FA172D10D3DQ34602263-1794C271-FFE5-4B4E-8444-5089296846DAQ34999190-99602E4C-A678-461D-99C9-23E74F6299F8Q35626096-FFBFD37F-D923-48E3-98D9-BFCFB11831ECQ36111590-13678EDB-E422-4CDF-B4F1-7330415991ACQ36485185-06300BB5-EEE1-47F2-8469-A3EC9C00A06EQ37255788-6EE7F02B-752F-421F-AED7-EBEBB06B85C0Q37565293-B08892CF-B615-4B26-BAA2-316BE848FA5DQ38039415-EABEE1E7-F0A0-4772-8299-D3ABA347ACFCQ38096055-71444266-B509-4386-98FA-361BAF87AAE6Q38199919-6C848F92-539F-462D-8C10-CF0501F272C1Q38244558-3B010202-1C07-4CFF-9AE2-DA6013801F5BQ38258197-EE34792D-39C7-4288-B242-653FE708AF0CQ38674188-9F84CE35-AB4E-4A68-9E0C-6BF0714110EAQ38797342-0587E9F4-AC33-4C3E-8265-3E15D789C02CQ39113061-DDDE1C6C-11EB-473E-B3B7-3791A3C0C1A4Q39120344-C6AFEF48-B32C-421F-9EF1-E69E9C8233DDQ39302531-1752B564-0757-4796-A62F-2CED8E4FAC3DQ41279386-6F5CCBEF-073B-4299-9E7D-AC290D155F39Q41610374-C965DAE0-7B20-4A7B-AB4D-59741B03C09FQ42316166-C17FB362-7C70-48AF-80D0-38B84A3D4969Q42789944-5B6867D6-F18A-4C6F-BFDE-64E430A45C75Q49569621-35B1EDA3-CA41-4D1C-B81D-07CF4973FAC4Q55251729-05FFA9C2-991D-432C-933C-A70394E5D153Q56657250-8F185ADD-FCC9-4D82-8B96-F96CED9F67DD
P2860
DangER: protein ovERload. Targeting protein degradation to treat myeloma
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
DangER: protein ovERload. Targeting protein degradation to treat myeloma
@ast
DangER: protein ovERload. Targeting protein degradation to treat myeloma
@en
DangER: protein ovERload. Targeting protein degradation to treat myeloma
@nl
type
label
DangER: protein ovERload. Targeting protein degradation to treat myeloma
@ast
DangER: protein ovERload. Targeting protein degradation to treat myeloma
@en
DangER: protein ovERload. Targeting protein degradation to treat myeloma
@nl
prefLabel
DangER: protein ovERload. Targeting protein degradation to treat myeloma
@ast
DangER: protein ovERload. Targeting protein degradation to treat myeloma
@en
DangER: protein ovERload. Targeting protein degradation to treat myeloma
@nl
P2860
P3181
P1433
P1476
DangER: protein ovERload. Targeting protein degradation to treat myeloma
@en
P2093
F. E. Davies
L. I. Aronson
P2860
P304
P3181
P356
10.3324/HAEMATOL.2012.064923
P407
P577
2012-08-01T00:00:00Z